Our Access-to-Medicine Strategy service helps pharmaceutical companies develop and implement strategies that improve access to medicines in underserved populations. We design access programs, affordability frameworks, and global health equity initiatives. Our approach balances patient access with commercial sustainability and ESG commitments.
How our access-to-medicine strategy service delivers value to your organization.
Comprehensive access program design including tiered pricing, donations, and capability building.
Affordability framework development balancing patient access with commercial sustainability.
Strategy alignment with Access to Medicine Index criteria to improve ESG performance.
Engagement with governments, NGOs, and global health organizations on access initiatives.
Comprehensive deliverables that provide actionable intelligence for your team.
A structured methodology that delivers results in four phases.
Assess current access performance, ATMI scores, and stakeholder expectations.
Develop access-to-medicine strategy with programs, pricing, and partnerships.
Engage key stakeholders including governments, NGOs, and patient communities.
Support implementation including program launch, monitoring, and impact assessment.
The Access to Medicine Index (ATMI) ranks pharmaceutical companies on their performance in improving access to medicine in low- and middle-income countries. It evaluates across multiple technical areas including pricing, licensing, donation, and capacity building.
We design access strategies that use tiered pricing, voluntary licensing, and targeted programs to improve access in LMIC while protecting commercial returns in higher-income markets. We build financial models to ensure sustainability.
Yes, we support ESG reporting on access-to-medicine initiatives aligned with GRI, SASB, and ATMI criteria, including metrics development and data collection frameworks.
Environmental footprint, social impact, and governance frameworks for pharmaceutical companies.
Learn moreGreen chemistry, carbon reduction, and waste management for pharmaceutical manufacturing.
Learn moreTiered pricing, voluntary licensing, and access programs for low- and middle-income countries.
Learn moreConnect with our team to discuss how our access-to-medicine strategy service can support your goals.
Schedule a Consultation